Journey Medical Corp (DERM): Total Liabilities
$62.74M
As of 2025-12-31
$66.24M
As of 2026-06-30
-10.7%
3-year compound annual growth
+8.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.74M | +4.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $60.17M | +6.5% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $56.50M | -35.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $88.18M | +59.6% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $55.24M | +32.7% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $41.61M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $190.57M | -21.6% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $4.58M | -34.2% |
Compare DERM, TNGX, NUVB, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗